Table 3.

Requirements for monitoring complete blood count during the treatment with CDK4/6 inhibitors [9, 19, 20]

	Cycle 1			Cycle 2			Cycles 3–4	Cycles 5–6	Cycles 6+
	day 1	day 14	day 15	day 1	day 14	day 15	day 1	day 1
Palbociclib	×		×	×		×	×	×	day 1a
Ribociclib	×	×		×	×		×	×	as indicated
Abemaciclib	×	×		×	×		×	as indicated	as indicated

^aFor patients who experience a maximum of grade 1 or 2 neutropenia in the first 6 cycles, complete blood counts for subsequent cycles should be monitored every 3 months, prior to the beginning of a cycle, and as clinically indicated.